NZ611628A - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Info

Publication number
NZ611628A
NZ611628A NZ611628A NZ61162811A NZ611628A NZ 611628 A NZ611628 A NZ 611628A NZ 611628 A NZ611628 A NZ 611628A NZ 61162811 A NZ61162811 A NZ 61162811A NZ 611628 A NZ611628 A NZ 611628A
Authority
NZ
New Zealand
Prior art keywords
laquinimod
improving
functional status
deterioration
multiple sclerosis
Prior art date
Application number
NZ611628A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ611628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ611628A publication Critical patent/NZ611628A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ611628A 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients NZ611628A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
NZ611628A true NZ611628A (en) 2015-06-26

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611628A NZ611628A (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG190449A1 (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
NZ602510A (en) * 2010-03-03 2014-11-28 Teva Pharma Treatment of lupus nephritis using laquinimod
SG183513A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
IN2015DN03219A (enExample) * 2012-09-27 2015-10-02 Teva Pharma
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе
HK1212936A1 (zh) 2012-11-07 2016-06-24 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
SG11201505818WA (en) * 2013-02-15 2015-08-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression
US20160331742A1 (en) * 2014-01-17 2016-11-17 Teva Pharmaceutical Industries, Ltd. Treatment of crohn's disease using low doses of laquinimod
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
CN112770748A (zh) * 2018-10-09 2021-05-07 美迪诺亚公司 异丁司特和干扰素-β的组合及其使用方法
CA3145269A1 (en) * 2019-07-22 2021-01-28 Michel BURCKLEN Use of ponesimod for the treatment of multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
PT2653873T (pt) * 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
CN107308162A (zh) * 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化

Also Published As

Publication number Publication date
UA111959C2 (uk) 2016-07-11
CN103260624B (zh) 2015-06-03
WO2012078591A8 (en) 2012-08-02
CN103260624A (zh) 2013-08-21
CA2820586A1 (en) 2012-06-14
PH12013501193A1 (en) 2013-07-15
JP2013544887A (ja) 2013-12-19
US20120142730A1 (en) 2012-06-07
EP2648732A1 (en) 2013-10-16
CL2013001602A1 (es) 2013-10-25
AU2011338647A8 (en) 2013-09-05
AU2017202055A1 (en) 2017-04-20
AU2011338647A1 (en) 2013-07-04
EA201390827A1 (ru) 2013-12-30
SG190449A1 (en) 2013-07-31
SG10201509831XA (en) 2015-12-30
BR112013014061A2 (pt) 2016-09-13
ZA201304237B (en) 2014-08-27
JP2017095476A (ja) 2017-06-01
PE20140872A1 (es) 2014-08-09
KR20130124518A (ko) 2013-11-14
WO2012078591A1 (en) 2012-06-14
EP2648732A4 (en) 2014-04-30
MX2013006464A (es) 2013-07-29
IL250726A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ589445A (en) Rasagiline for parkinson's disease modification
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
HRP20180237T4 (hr) Metode za liječenje hcv-a
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
NZ602510A (en) Treatment of lupus nephritis using laquinimod
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
UA92584C2 (ru) Применение мелоксикама для лечения респираторных заболеваний у свиней
NZ605469A (en) Nalbuphine-based formulations and uses thereof
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
IN2012DN06616A (enExample)
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
JP2013516493A5 (enExample)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2016 BY DENNEMEYER + CO

Effective date: 20151124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2017 BY DENNEMEYER + CO

Effective date: 20161129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2018 BY DENNEMEYER + CO

Effective date: 20171122

LAPS Patent lapsed